BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 33345655)

  • 1. Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia.
    Chen X; Othus M; Wood BL; Walter RB; Becker PS; Percival ME; Abkowitz JL; Appelbaum FR; Estey EH
    Leuk Lymphoma; 2021 May; 62(5):1226-1233. PubMed ID: 33345655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia.
    Kao HW; Sanada M; Liang DC; Lai CL; Lee EH; Kuo MC; Lin TL; Shih YS; Wu JH; Huang CF; Ogawa S; Shih LY
    Neoplasia; 2011 Nov; 13(11):1035-42. PubMed ID: 22131879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts.
    Shen K; Hu DY; Zhang ZB; Guo YS; Zhang FH; Chen SN
    Int J Lab Hematol; 2023 Jun; 45(3):344-352. PubMed ID: 36860196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Grob T; Al Hinai ASA; Sanders MA; Kavelaars FG; Rijken M; Gradowska PL; Biemond BJ; Breems DA; Maertens J; van Marwijk Kooy M; Pabst T; de Weerdt O; Ossenkoppele GJ; van de Loosdrecht AA; Huls GA; Cornelissen JJ; Beverloo HB; Löwenberg B; Jongen-Lavrencic M; Valk PJM
    Blood; 2022 Apr; 139(15):2347-2354. PubMed ID: 35108372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
    Owattanapanich W; Herzig J; Jahn N; Panina E; Ruchutrakool T; Kungwankiattichai S; Issaragrisil S; Döhner H; Döhner K
    Ann Hematol; 2021 Aug; 100(8):1983-1993. PubMed ID: 33839881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
    Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
    J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.
    Chan GC; Wang WC; Raimondi SC; Behm FG; Krance RA; Chen G; Freiberg A; Ingram L; Butler D; Head DR
    Leukemia; 1997 Feb; 11(2):206-11. PubMed ID: 9009082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Niparuck P; Police P; Noikongdee P; Siriputtanapong K; Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Siriboonpiputtana T
    Diagn Pathol; 2021 Oct; 16(1):100. PubMed ID: 34717674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What biologic factors predict for transformation to AML?
    Bejar R
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):341-345. PubMed ID: 30466744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.
    Estey E; Hasserjian RP; Döhner H
    Blood; 2022 Jan; 139(3):323-332. PubMed ID: 34111285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
    De Witte T; Muus P; De Pauw B; Haanen C
    Cancer; 1990 Sep; 66(5):831-7. PubMed ID: 2386911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
    Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
    Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia-related changes: A single institution experience.
    Gao L; Hyter S; Zhang D; Kelting S; Woodroof J; Abdallah AO; Yacoub A; McGuirk J; Abdelhakim H; Godwin AK; Cui W
    Int J Lab Hematol; 2022 Aug; 44(4):738-749. PubMed ID: 35352484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-lineage level-targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes.
    Yokoyama K; Shimizu E; Yokoyama N; Nakamura S; Kasajima R; Ogawa M; Takei T; Ito M; Kobayashi A; Yamaguchi R; Imoto S; Miyano S; Tojo A
    Blood Adv; 2018 Oct; 2(19):2513-2521. PubMed ID: 30282643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes.
    Yanada M; Mizuno S; Yamasaki S; Harada K; Konuma T; Tamaki H; Shingai N; Uchida N; Ozawa Y; Tanaka M; Onizuka M; Sawa M; Nakamae H; Shiratori S; Matsuoka KI; Eto T; Kawakita T; Maruyama Y; Ichinohe T; Kanda Y; Atsuta Y; Aoki J; Yano S
    Leuk Lymphoma; 2021 Dec; 62(14):3411-3419. PubMed ID: 34348554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML).
    Yun S; Geyer SM; Komrokji RS; Al Ali NH; Song J; Hussaini M; Sweet KL; Lancet JE; List AF; Padron E; Sallman DA
    Leukemia; 2021 Apr; 35(4):1145-1155. PubMed ID: 32728186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years.
    De Witte T; Muus P; De Pauw B; Haanen C
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():33-5. PubMed ID: 2697396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia.
    Martín-Izquierdo M; Abáigar M; Hernández-Sánchez JM; Tamborero D; López-Cadenas F; Ramos F; Lumbreras E; Madinaveitia-Ochoa A; Megido M; Labrador J; Sánchez-Real J; Olivier C; Dávila J; Aguilar C; Rodríguez JN; Martín-Nuñez G; Santos-Mínguez S; Miguel-García C; Benito R; Díez-Campelo M; Hernández-Rivas JM
    Haematologica; 2021 Aug; 106(8):2215-2223. PubMed ID: 32675227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.